146 related articles for article (PubMed ID: 28084585)
1. Estimating the Cost of Illness of Giant Cell Arteritis in the United States.
Babigumira JB; Li M; Boudreau DM; Best JH; Garrison LP
Rheumatol Ther; 2017 Jun; 4(1):111-119. PubMed ID: 28084585
[TBL] [Abstract][Full Text] [Related]
2. Trajectory of Healthcare Resource Utilization in Giant Cell Arteritis: A Population-based Study.
Mohammad AJ; Turkiewicz A; Stamatis P; Turesson C; Englund M; Kiadaliri A
J Rheumatol; 2021 Aug; 48(8):1307-1313. PubMed ID: 33649063
[TBL] [Abstract][Full Text] [Related]
3. Phase-Specific Healthcare Costs Associated With Giant Cell Arteritis in Ontario, Canada.
Junek M; Barra L; Kopp A; Felfeli T; Gatley J; Widdifield J
J Rheumatol; 2024 Jul; 51(7):696-702. PubMed ID: 38561188
[TBL] [Abstract][Full Text] [Related]
4. Healthcare Use and Direct Cost of Giant Cell Arteritis: A Population-based Study.
Koster MJ; Achenbach SJ; Crowson CS; Maradit-Kremers H; Matteson EL; Warrington KJ
J Rheumatol; 2017 Jul; 44(7):1044-1050. PubMed ID: 28461641
[TBL] [Abstract][Full Text] [Related]
5. Adverse Events in Giant Cell Arteritis and Rheumatoid Arthritis Patient Populations: Analyses of Tocilizumab Clinical Trials and Claims Data.
Gale S; Trinh H; Tuckwell K; Collinson N; Stone JH; Sarsour K; Pei J; Best J; Birchwood C; Mohan SV
Rheumatol Ther; 2019 Mar; 6(1):77-88. PubMed ID: 30707391
[TBL] [Abstract][Full Text] [Related]
6. Data linkage analysis of giant cell arteritis in Italy: Healthcare burden and cost of illness in the Italian region of Friuli Venezia Giulia (2001-2017).
Valent F; Bond M; Cavallaro E; Treppo E; Rosalia Maria DR; Tullio A; Dejaco C; De Vita S; Quartuccio L
Vasc Med; 2020 Apr; 25(2):150-156. PubMed ID: 31804152
[TBL] [Abstract][Full Text] [Related]
7. Projected worldwide disease burden from giant cell arteritis by 2050.
De Smit E; Palmer AJ; Hewitt AW
J Rheumatol; 2015 Jan; 42(1):119-25. PubMed ID: 25362658
[TBL] [Abstract][Full Text] [Related]
8. The association of gout with incident giant cell arteritis in older adults.
Singh JA; Cleveland JD
Joint Bone Spine; 2019 Mar; 86(2):219-224. PubMed ID: 29885976
[TBL] [Abstract][Full Text] [Related]
9. Hospitalization rates and utilization among patients with giant cell arteritis: A population-based study from 1987 to 2012.
Michet CJ; Achenbach SJ; Crowson CS; Matteson EL
Semin Arthritis Rheum; 2015 Aug; 45(1):70-4. PubMed ID: 25824865
[TBL] [Abstract][Full Text] [Related]
10. Incremental Costs in Giant Cell Arteritis.
Mounié M; Costa N; Sailler L; Lapeyre-Mestre M; Bourrel R; Savy N; Molinier L; Pugnet G
Arthritis Care Res (Hoboken); 2018 Jul; 70(7):1074-1081. PubMed ID: 28973818
[TBL] [Abstract][Full Text] [Related]
11. Effect of diabetes mellitus on giant cell arteritis.
Abel AS; Yashkin AP; Sloan FA; Lee MS
J Neuroophthalmol; 2015 Jun; 35(2):134-8. PubMed ID: 25602744
[TBL] [Abstract][Full Text] [Related]
12. Mortality among Patients with Giant Cell Arteritis: A Large-scale Population-based Cohort Study.
Ben-Shabat N; Tiosano S; Shovman O; Comaneshter D; Shoenfeld Y; Cohen AD; Amital H
J Rheumatol; 2020 Sep; 47(9):1385-1391. PubMed ID: 31839591
[TBL] [Abstract][Full Text] [Related]
13. Burden, Causes, and Outcomes of Hospitalization in Patients With Giant Cell Arteritis: A US National Cohort Study.
Goulabchand R; Qian AS; Nguyen NH; Singh AG; Roubille C; Parreau S; Singh N; Singh S
Arthritis Care Res (Hoboken); 2023 Aug; 75(8):1830-1837. PubMed ID: 36576029
[TBL] [Abstract][Full Text] [Related]
14. Mortality in Patients With Giant Cell Arteritis: A Cohort Study in UK Primary Care.
Li L; Neogi T; Jick S
Arthritis Care Res (Hoboken); 2018 Aug; 70(8):1251-1256. PubMed ID: 29409137
[TBL] [Abstract][Full Text] [Related]
15. Survival and death causes of patients with giant cell arteritis in Western Norway 1972-2012: a retrospective cohort study.
Brekke LK; Fevang BS; Diamantopoulos AP; Assmus J; Esperø E; Gjesdal CG
Arthritis Res Ther; 2019 Jun; 21(1):154. PubMed ID: 31238961
[TBL] [Abstract][Full Text] [Related]
16. Does glucocorticosteroid-resistant large-vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature.
Kötter I; Henes JC; Wagner AD; Loock J; Gross WL
Clin Exp Rheumatol; 2012; 30(1 Suppl 70):S114-29. PubMed ID: 22640655
[TBL] [Abstract][Full Text] [Related]
17. Incidence of Severe Infections and Infection-Related Mortality During the Course of Giant Cell Arteritis: A Multicenter, Prospective, Double-Cohort Study.
Schmidt J; Smail A; Roche B; Gay P; Salle V; Pellet H; Duhaut P
Arthritis Rheumatol; 2016 Jun; 68(6):1477-82. PubMed ID: 26815885
[TBL] [Abstract][Full Text] [Related]
18. Risk of Potential Glucocorticoid-Related Adverse Events in Patients with Giant Cell Arteritis: Results from a USA-Based Electronic Health Records Database.
Best JH; Kong AM; Unizony S; Tran O; Michalska M
Rheumatol Ther; 2019 Dec; 6(4):599-610. PubMed ID: 31656021
[TBL] [Abstract][Full Text] [Related]
19. Giant cell arteritis and vascular disease-risk factors and outcomes: a cohort study using UK Clinical Practice Research Datalink.
Li L; Neogi T; Jick S
Rheumatology (Oxford); 2017 May; 56(5):753-762. PubMed ID: 28077689
[TBL] [Abstract][Full Text] [Related]
20. Healthcare cost attributable to recently-diagnosed breast cancer in a privately-insured population in the United States.
Fu AZ; Jhaveri M
J Med Econ; 2012; 15(4):688-94. PubMed ID: 22397589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
